-
Pilot Study of 89-Zr Panitumumab in Pancreas Cancer
Not Recruiting
More
The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular
imaging agent in patients with (metastatic) pancreas cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alexander A Valencia, 650-498-5185.
Lead Sponsor
Stanford Investigators
View full details
-
Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases
Not Recruiting
More
Patients are invited to participate in a research study of liver perfusion (how blood flows
to the liver over time). Researchers hope to learn whether perfusion characteristics of liver
metastases may be predictive of response to treatment and whether liver perfusion
characteristics can be used to follow response to treatment. Patients were selected as a
possible participant in this study because they are identified as having liver metastases
Stanford is currently not accepting patients for this trial.
For more information, please contact Risa Jiron, 650-736-1598.
Lead Sponsor
Stanford Investigators
View full details
-
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
Not Recruiting
More
The primary objective of this study is to compare the overall survival (OS) of subjects with
previously treated metastatic pancreatic cancer treated with cyclophosphamide
(CY)/nivolumab/GVAX pancreas vaccine followed by nivolumab/CRS-207 (Arm A) to subjects
treated with CY/GVAX pancreas vaccine followed by CRS-207 (Arm B).
Stanford is currently not accepting patients for this trial.
For more information, please contact Melissa Worman, 650-725-0379.
Stanford Investigators
View full details
-
Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Recruiting
More
This trial is designed to evaluate multiple clinical hypotheses and mechanistically-defined
combinations to evaluate the safety and efficacy of first-line chemo-immunotherapy
combinations in participants with metastatic pancreatic ductal adenocarcinoma (mPDAC).
Stanford Investigators
View full details
-
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Not Recruiting
More
This randomized phase II trial studies how well pazopanib hydrochloride works in treating
patients with carcinoid tumors that are growing, spreading, or getting worse. Pazopanib
hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ben Priestley, 650-723-2990.
Stanford Investigators
View full details
-
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors
Not Recruiting
More
This Phase I, multicenter, first-in-human, open-label, dose-escalation study will evaluate
the safety, tolerability, and pharmacokinetics of atezolizumab (MPDL3280A) administered as
single agent to participants with locally advanced or metastatic solid malignancies or
hematologic malignancies. The study will be conducted in two cohorts: Dose-escalation cohort
and Expansion cohort.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Pitsiouni, 650-721-6977.
Stanford Investigators
View full details
-
Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Not Recruiting
More
The main purposes of this study are to learn how effective the study drug combinations are in
treating patients with metastatic pancreatic adenocarcinoma. The drug combinations are
APX005M+Nivolumab+Gemcitabine+nab-Paclitaxel, or APX005M+Gemcitabine+nab-Paclitaxel.
Stanford is currently not accepting patients for this trial.
For more information, please contact Stanford Cancer Clinical Trials Office, Outreach, 650-498-7061.
Stanford Investigators
View full details
-
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
Recruiting
More
This phase III trial studies how well vitamin D3 given with standard chemotherapy and
bevacizumab works in treating patients with colorectal cancer that has spread to other parts
of the body. Vitamin D3 helps the body use calcium and phosphorus to make strong bones and
teeth. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, oxaliplatin, and
irinotecan hydrochloride, work in different ways to stop the growth of tumor cells by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy
with monoclonal antibodies, such as bevacizumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Giving vitamin
D3 with chemotherapy and bevacizumab may work better in shrinking or stabilizing colorectal
cancer. It is not yet known whether giving high-dose vitamin D3 in addition to chemotherapy
and bevacizumab would extend patients' time without disease compared to the usual approach
(chemotherapy and bevacizumab).
Stanford Investigators
View full details
-
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
Recruiting
More
This phase II trial compares two treatment combinations: gemcitabine hydrochloride and
nab-paclitaxel, or fluorouracil, leucovorin calcium, and liposomal irinotecan in older
patients with pancreatic cancer that has spread to other places in the body (metastatic).
Drugs used in chemotherapy, such as gemcitabine hydrochloride, nab-paclitaxel, fluorouracil,
leucovorin calcium, and liposomal irinotecan, work in different ways to stop the growth of
tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them
from spreading. This study may help doctors find out which treatment combination is better at
prolonging life in older patients with metastatic pancreatic cancer.
Stanford Investigators
View full details
-
Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project
Not Recruiting
More
To determine whether using a radiolabelled analog of 5-FU, [18F]-5-fluorouracil, for PET/CT
imaging can visually demonstrate differential chemotherapy delivery to known tumor sites
before and after administration of bevacizumab and determine the optimal timing of
bevacizumab administration to maximize the chemotherapy delivery into the tumor for improved
cancer treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maurice Zissen, 6507361365.
Lead Sponsor
Stanford Investigators
View full details
-
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Not Recruiting
More
The purpose of this research is to evaluate the effectiveness and safety of a combination of
capecitabine, temozolomide and bevacizumab in the treatment of advanced pancreatic
neuroendocrine tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ben Priestley, 650-723-2990.
Stanford Investigators
View full details
-
Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
Not Recruiting
More
A research study of liver perfusion (how blood flows to the liver over time). We hope to
learn whether perfusion characteristics of liver masses may be predictive of response to
treatment and whether liver perfusion characteristics can be used to follow response to
treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Elizabeth Chitouras, 650-498-0623.
Lead Sponsor
Stanford Investigators
View full details
-
Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer
Not Recruiting
More
A research study of rectal cancer perfusion (how blood flows to the rectum over time). We
hope to learn whether perfusion characteristics of rectal masses may be predictive of
response to treatment and whether rectal perfusion characteristics can be used to follow
response to treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 650-736-0798.
Lead Sponsor
Stanford Investigators
View full details
-
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Not Recruiting
More
This phase III trial investigates how well nivolumab after combined modality therapy works in
treating patients with high risk stage II-IIIB anal cancer. Immunotherapy with monoclonal
antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread.
Stanford is currently not accepting patients for this trial.
For more information, please contact Site Public Contact, 650-498-7061.
Stanford Investigators
View full details
-
A Study of XmAb®18087 in Subjects With NET and GIST
Not Recruiting
More
This is a Phase 1, multiple dose, ascending dose escalation study; to define a MTD/RD and
regimen consisting of a first "priming" dose and escalated subsequent doses of XmAb18087; to
describe safety and tolerability; to assess PK and immunogenicity; and to preliminarily
assess anti-tumor activity of XmAb18087 in subjects with advanced NET or GIST.
The study will enroll dosing cohorts to establish a MTD/RD and regimen in subjects with
advanced NET or GIST, then enroll additional subjects into separate NET and GIST expansion
cohorts to collect additional data on safety and potential efficacy of XmAb18087.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
Not Recruiting
More
CO40939 is a Phase Ib, open-label, multicenter, single-arm study designed to evaluate the
safety, efficacy, pharmacokinetics, and immunogenicity of cibisatamab in combination with
atezolizumab administered after pretreatment with obinutuzumab in patients with Stage IV
microsatellite stable (MSS) metastatic colorectal cancer (mCRC) whose tumors have high
carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expression and who have
progressed on two or more chemotherapy regimens. The study is composed of a safety run-in and
an exploratory part.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
Not Recruiting
More
This randomized phase III trial studies oxaliplatin, leucovorin calcium, fluorouracil, and
bevacizumab to see how well they work compared to oxaliplatin, leucovorin calcium, and
fluorouracil in treating patients who have undergone surgery for stage II colon cancer. Drugs
used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as
bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet
known whether giving combination chemotherapy together with bevacizumab is more effective
than combination chemotherapy alone in treating colon cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nancy Mori, 6507240201.
Stanford Investigators
View full details
-
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Not Recruiting
More
This phase III trial studies combination chemotherapy and atezolizumab to see how well it
works compared with combination chemotherapy alone in treating patients with stage III colon
cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination
chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such
as atezolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Giving combination chemotherapy with
atezolizumab may work better than combination chemotherapy alone in treating patients with
colon cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sigurdis Haraldsdottir, 650-498-7061.
Stanford Investigators
View full details
-
Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
Not Recruiting
More
To study the safety and feasibility of stereotactic radiation dose escalation following
neoadjuvant chemotherapy with concurrent conventionally fractionated radiation, by evaluating
the acute and late toxicity of treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laurie Ann Columbo, 6507360792.
Lead Sponsor
Stanford Investigators
View full details
-
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Not Recruiting
More
This study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab in
combination with bevacizumab, bevacizumab + oxaliplatin, leucovorin and 5-fluorouracil (5-FU)
(FOLFOX), vanucizumab, nab-paclitaxel + gemcitabine, FOLFOX, or 5-FU + cisplatin, in
participants with solid tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Not Recruiting
More
To investigate bevacizumab in combination with carboplatin and capecitabine for patients with
unresectable or metastatic GEJ or gastric cancers. We hope that by adding bevacizumab to
standard chemotherapy for this patient population we will improve Progression Free Survival
by 90% over historical controls.
Stanford is currently not accepting patients for this trial.
For more information, please contact Prachi Nandoskar, 6507250438.
Stanford Investigators
View full details
-
Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer
Not Recruiting
More
This study will evaluate the safety and tolerability of a personalized live, attenuated,
double-deleted Listeria monocytogenes (pLADD) treatment in adults with metastatic colorectal
cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Flordeliza Mendoza, CCRC, 650-724-2056.
Stanford Investigators
View full details
-
A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Not Recruiting
More
This is an open-label, multicenter, dose-escalation and expansion Phase Ib clinical study of
RO6958688 in combination with atezolizumab. Part I of the study is subdivided into parts IA
and IB. Part IA is dose escalation with a starting dose of 5 mg of RO6958688 given QW (once a
week) and a fixed, flat dose of 1200 mg given Q3W (every 3 weeks) of atezolizumab, to
evaluate the safety and determine the MTD of RO6958688 in combination with atezolizumab. Part
IB is a dose/schedule finding part that will explore different administration schedules of
RO6958688 in combination with atezolizumab (1200 mg Q3W) to establish the appropriate
dose/schedule of RO6958688 in combination with atezolizumab.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Not Recruiting
More
Study BP29541 is a first-in-human, open-label, multi-center, dose-escalation Phase I clinical
study of single-agent RO6958688 in participants with locally advanced and/or metastatic
carcinoembryonic antigen (CEA) positive solid tumors who have progressed on standard
treatment, are intolerant to standard of care (SOC), and/or are non-amenable to SOC. The
study will be conducted in two parts. Part I of the study will investigate the safety and
pharmacokinetics of a single dose of RO6958688 in single participant cohorts with dosing
starting from a minimal anticipated biological effect level dose of 0.05 milligrams (mg) and
up to a maximum dose of 2.5 mg. Part II will establish the appropriate therapeutic dose based
on safety, pharmacokinetics, and the maximum tolerated dose (MTD) of RO6958688 for the once
per week (QW) regimen, every three weeks (Q3W) regimen, and for the step up dosing regimen.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer
Not Recruiting
More
The primary objectives of this study are: (Phase 1b) to investigate the safety and
tolerability and to determine the recommended Phase 2 dose (RP2D) for magrolimab in
combination with cetuximab; and (Phase 2) to evaluate overall response rate (ORR) of
magrolimab in combination with cetuximab in participants with Kirsten rat sarcoma 2 viral
oncogene homolog (KRAS) mutant and KRAS wild-type colorectal cancer (CRC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Not Recruiting
More
The purpose of this study is to determine if the True Human Monoclonal antibody Xilonix
(MABp1) can prolong the life of colorectal carcinoma patients that are refractory to standard
therapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Flordeliza Mendoza, 650-724-2056.
Stanford Investigators
View full details
-
Permission to Collect Blood Over Time for Research
Not Recruiting
More
To determine whether biomarkers assessed in blood samples can be used to detect individuals
at risk for developing blood clots or worsening of their underlying disease. The ultimate
goal of the study is to identify key biomarkers derived from blood that are most
characteristic and informative of individuals who will go on to develop a clotting
complication.
Stanford is currently not accepting patients for this trial.
For more information, please contact Fizaa Ahmed, 650-725-6409.
Lead Sponsor
Stanford Investigators
View full details
-
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Not Recruiting
More
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to
evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene
cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an
engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed
Not Recruiting
More
This large, non-randomized observational study is being conducted to provide data about the
impact of ethnic origin on outcomes and resource utilization during the 2nd line treatment of
non-small cell lung cancer (NSCLC) in a routine medical care setting.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer
Not Recruiting
More
This pilot phase I/II trial studies the side effects and best of dose ipilimumab when given
together with local radiation therapy and to see how well it works in treating patients with
recurrent melanoma, non-Hodgkin lymphoma, colon, or rectal cancer. Monoclonal antibodies,
such as ipilimumab, can block cancer growth in different ways. Some block the ability of
cancer cells to grow and spread. Others find cancer cells and help kill them or carry
cancer-killing substances to them. Radiation therapy uses high energy x rays to kill cancer
cells. Giving monoclonal antibody therapy together with radiation therapy may be an effective
treatment for melanoma, non-Hodgkin lymphoma, colon, or rectal cancer
Stanford is currently not accepting patients for this trial.
For more information, please contact Erin Waller, 650-725-0379.
Lead Sponsor
Stanford Investigators
View full details
-
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
Not Recruiting
More
The primary purpose of this study is to determine the maximally tolerated dose (MTD) of
HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus
carboplatin, cisplatin plus etoposide, or docetaxel.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Vargas, 650-723-0371 .
Stanford Investigators
View full details
-
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Not Recruiting
More
This is a Phase 1b/2, multi-center study to assess the safety and efficacy of ibrutinib in
combination with durvalumab (MEDI4736) in participants with relapsed or refractory solid
tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Not Recruiting
More
This randomized phase III trial studies octreotide acetate and recombinant interferon alfa-2b
to see how well it works compared to octreotide acetate and bevacizumab in treating patients
with high-risk neuroendocrine tumors that have spread to other places in the body
(metastatic) or spread from where it started to nearby tissue or lymph nodes (locally
advanced). Octreotide acetate and recombinant interferon alfa-2b may interfere with the
growth of tumor cells and slow the growth of cancer. Monoclonal antibodies, such as
bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet
known whether giving octreotide acetate together with recombinant interferon alfa-2b is more
effective than giving octreotide acetate together with bevacizumab in treating patients with
neuroendocrine tumor.
Stanford is currently not accepting patients for this trial.
For more information, please contact Deryn Warner, 6507232876 x 25067.
Stanford Investigators
View full details
-
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
Not Recruiting
More
This is a multi-center, 2-part phase 1b/2 study of AMG 655 in combination with AMG 479 to be
conducted in the United States and Spain.
Part 1 is a dose escalation segment to identify a dose of AMG 655 in combination with AMG 479
that is safe and tolerable.
Part 2 will evaluate the safety and estimate the efficacy of AMG 655 at the dose selected in
Part 1 in combination with AMG 479 for the treatment of patients with advanced NSCLC
(non-squamous histology; squamous histology), CRC, pancreatic cancer, ovarian cancer, and
sarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Dana Supan, 6507361694.
Stanford Investigators
View full details
-
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Not Recruiting
More
The purpose of this study is to determine whether or not XL184 demonstrates anti-tumor
activity in selected tumor types under a randomized discontinuation trial (RDT) design.
Subjects who have responded to study drug after 12 weeks of open-label XL184 administration
will continue to take XL184. Subjects who are clearly progressing will discontinue study
treatment and subjects who demonstrate stable disease will be randomized to either XL184 or
placebo. For individual patients, once disease progression is observed, the blind will be
broken and subjects who were randomized to placebo will be offered the option to receive
open-label XL184. Subjects who progressed while taking XL184 will discontinue study
treatment.
Emerging data may support enrollment in an open-label, non-randomized expansion cohort (NRE).
There will be NRE cohorts for prostate and ovarian cancers.
Stanford is currently not accepting patients for this trial.
For more information, please contact Dana Supan, 6507361694.
Stanford Investigators
View full details
-
A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Not Recruiting
More
This is a single-arm, multicenter, Phase Ib study designed to describe the effect of GDC-0449
on the pharmacokinetics of rosiglitazone and oral contraceptives in patients with advanced
solid tumors who are refractory to treatment or for whom no standard therapy exists.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
Not Recruiting
More
This is a study of CDX-1127, a therapy that targets the immune system and may act to promote
anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias
and lymphomas), as well as patients with select types of solid tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Vargas, 650-723-0371.
Stanford Investigators
View full details
-
A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
Not Recruiting
More
The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects
with advanced solid tumors and to determine a phase 2 dose.
Stanford is currently not accepting patients for this trial.
For more information, please contact Dana Supan, 6507361694.
Stanford Investigators
View full details
-
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
Not Recruiting
More
This protocol (NLG0705) provides a mechanism for the 15-year follow-up period that the FDA
requires for all participants in gene transfer protocols and assures that adequate follow-up
can be maintained for subjects who have received at least one dose of algenpantucel-L.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Not Recruiting
More
This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group
phase III study comparing treatment with Lutathera plus best supportive care (30 mg
Octreotide LAR) to treatment with high dose (60 mg) Octreotide LAR in participants with
metastasized or locally advanced, inoperable, somatostatin receptor positive, histologically
proven midgut carcinoid tumours with progression despite LAR treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Flordeliza Mendoza, 650-724-2056.
Stanford Investigators
View full details
-
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Not Recruiting
More
Advanced Accelerator Applications is currently pursuing marketing approval for
177Lu-DOTA0-Tyr3-Octreotate (Lutathera). This expanded access therapeutic protocol aims to
allow patients suffering from inoperable, somatostatin receptor positive, neuroendocrine
tumors, progressive under somatostatin analogue therapy to access the investigational
product, 177Lu-DOTA0-Tyr3-Octreotate (Lutathera), prior to its commercial availability.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Not Recruiting
More
This multi-institutional trial aims to evaluate the potential benefit and side effects of
adding fractionated stereotactic body radiotherapy/surgery (SBRT) before and after
chemotherapy with gemcitabine for locally advanced pancreatic cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laurie Ann Columbo, 650-736-0792.
Lead Sponsor
Stanford Investigators
View full details
-
Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours
Not Recruiting
More
This is a Phase 3, prospective, multi-center, randomized, double-blind, study evaluating the
efficacy and safety of LAN plus BSC versus placebo plus BSC for the treatment of
well-differentiated, metastatic and/or unresectable, typical or atypical lung NETs.
This study contains two phases: the Double-Blind (DB) Phase, and the Open Label (OL)
Extension Phase. The DB Phase includes: Screening, Baseline and Treatment period. The OL
Extension Phase will consist of two periods: Treatment Period and Follow-Up Period.
The primary objective will be to compare the antitumour efficacy of Lanreotide Autogel/Depot
120 mg (LAN) plus Best Supportive Care (BSC) every 28 days versus placebo plus BSC, in terms
of progression-free survival (PFS), measured by central review using Response Evaluation
Criteria in Solid Tumours (RECIST) v1.1 criteria, every 12 weeks, in subjects with
unresectable and/or metastatic well differentiated, typical or atypical lung neuroendocrine
tumours.
Recent updates of National Cancer Institute Cancer Network (NCCN) & European Neuroendocrine
Tumor Society (ENETS) guidelines recommend SSA in first line for the treatment of
locoregional unresectable or metastatic lung NETs as an option beyond
'observation''observation' leading to slow and difficult recruitment in SPINET study.
Consequently, it was decided to prematurely stop the recruitment in the SPINET study and to
transition all subjects still treated in the double-blind phase to the open label (OL)
extension following respective country approvals of Amendment #5.
The new aim of this Phase 3, multicenter, prospective, randomized placebo-controlled clinical
study is to describe the antitumor efficacy and safety of Lanreotide Autogel/Depot 120 mg
(LAN) plus Best Supportive Care (BSC) in subjects with well-differentiated, metastatic and/or
unresectable, typical or atypical, lung NETs.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase 1 Trial of Oral Ixabepilone
Not Recruiting
More
This Phase 1 study of oral ixabepilone given every 6 hours for 3 doses on Day 1, every 21
days, was a dose-finding study designed to determine the maximum tolerated dose (MTD) and
safety of this dosing schedule in participants with advanced cancer
Stanford is currently not accepting patients for this trial.
For more information, please contact Dana Supan, 6507361694.
Stanford Investigators
View full details
-
Phase I Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases
Not Recruiting
More
Up to twenty-two patients will be enrolled in this study to receive autologous dendritic
cells (DCs) administered intratumorally into liver metastases following radiofrequency
thermal ablation of those lesions. Patients will receive two vaccinations of DCs at monthly
intervals. A dose escalation study of DCs will be included in this study in an attempt to
define the maximum tolerated dose of administered DCs.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jenna Rogers, 6507234467.
Lead Sponsor
Stanford Investigators
View full details
-
Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer
Not Recruiting
More
To determine the safety, feasibility and appropriate dendritic cell dose to vaccinate
patients with pancreas cancer
Stanford is currently not accepting patients for this trial.
For more information, please contact Jenna Rogers, 6507234467.
Stanford Investigators
View full details
-
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Not Recruiting
More
In this study, participants with previously-treated locally-advanced unresectable or
metastatic mismatched repair (MMR) deficient or microsatellite instability-high (MSI-H)
colorectal carcinoma (CRC) will be treated with pembrolizumab (MK-3475, KEYTRUDA®)
monotherapy.
There will be two cohorts in this study: Cohort A and Cohort B. For Cohort A, participants
are required to have been previously treated with standard therapies, which must include
fluoropyrimidine, oxaliplatin, and irinotecan. Enrollment into Cohort A has been completed.
For Cohort B, participants are required to have been previously treated with at least one
line of systemic standard of care therapy: fluoropyrimidine + oxaliplatin or fluoropyrimidine
+ irinotecan +/ - anti-vascular endothelial growth factor (VEGF)/ epidermal growth factor
regulator (EGFR) monoclonal antibody.
The primary hypothesis is that Objective Response Rate (ORR) based on Response Evaluation
Criteria in Solid Tumors v 1.1 (RECIST 1.1) assessed by central imaging vendor in
participants with locally advanced unresectable or metastatic MMR deficient or MSI high CRC
is greater than 15%.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors
Not Recruiting
More
This is a Phase Ib, open-label, multicenter study designed to assess the safety,
tolerability, and pharmacokinetics of coadministration of intravenous (IV) dosing of
atezolizumab (an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody) and oral
dosing of cobimetinib in participants with metastatic or locally advanced cancer for which no
standard therapy exists.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 650-736-4112.
Stanford Investigators
View full details
-
A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer
Not Recruiting
More
The objectives of this study are to:
1. To assess dose-limiting toxicities (DLTs) of capecitabine +/- oxaliplatin in a
combination regimen with capecitabine and radiotherapy (Phase 1)
2. To determine the maximum-tolerated dose (MTD) when capecitabine
- oxaliplatin in a combination regimen with capecitabine and radiotherapy (Phase 1)
3. To determine the pathologic response rate of cetuximab +/- oxaliplatin in combination
with capecitabine and radiotherapy (Phase 2)
Stanford is currently not accepting patients for this trial.
For more information, please contact Heidi Kaiser, 6507240079.
Stanford Investigators
View full details
-
Study of GSK1363089 in Metastatic Gastric Cancer
Not Recruiting
More
This clinical study is being conducted at multiple sites to determine the best confirmed
response rate, safety, and tolerability of GSK1363089 treatment in metastatic gastric
carcinoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Heidi Kaiser, 6507240079.
Stanford Investigators
View full details
-
Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
Not Recruiting
More
In this study, participants with MSI-H or dMMR advanced colorectal carcinoma will be randomly
assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of
care (SOC) chemotherapy regimens for the treatment of advanced colorectal carcinoma. The
primary study hypothesis is that pembrolizumab will prolong progression-free survival (PFS)
or overall survival (OS) compared to current SOC chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Not Recruiting
More
This phase I/II trial is designed to efficiently identify the regimen limiting toxicity (RLT)
and recommended phase 2 dose (RP2D) for the combination of the immunotherapeutic agent
indoximod when administered in combination with standard of care chemotherapy gemcitabine
plus nab-paclitaxel in subjects with metastatic adenocarcinoma of the pancreas. All subjects
will receive the same standard gemcitabine plus nab-paclitaxel regimen, plus indoximod in
doses increasing from 600 mg twice daily to, potentially, 1200 mg twice daily.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melissa Worman, 650-725-0379.
Stanford Investigators
View full details
-
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Not Recruiting
More
PURPOSE: This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium,
and fluorouracil together to compare how well they work when given together with or without
celecoxib in treating patients with stage III colon cancer previously treated with surgery.
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and
fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Celecoxib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. It is not yet known whether giving
oxaliplatin, leucovorin calcium, and fluorouracil is more effective with or without celecoxib
in treating colon cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ben Priestley, 650-723-2990 (Palo Alto and South Bay locations).
Stanford Investigators
View full details
-
Telotristat Etiprate for Carcinoid Syndrome Therapy
Not Recruiting
More
The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on
the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid (5-HIAA)
levels.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Dauriac, 650-736-0697.
Stanford Investigators
View full details
-
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Not Recruiting
More
This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients
with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene.
This trial will also allow patients from a Phase 3 trial who received standard of care
chemotherapy (Study A8081007) to receive PF-02341066.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Not Recruiting
More
This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus
pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific
gene profile involving the ALK gene after failure of one previous chemotherapy regimen that
included one platinum drug.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer
Not Recruiting
More
In Phase 1 of this study, the purpose is to evaluate the safety, tolerability, and highest
safe dose of the multiple receptor tyrosine kinase inhibitor (including VEGFR2, MET, and RET)
XL184 in combination with the EGFR inhibitor erlotinib administered to adults with
Non-Small-Cell Lung Cancer (NSCLC). In Phase 2 of this study, the purpose is to evaluate the
objective response rate of daily oral administration of XL184 with or without erlotinib in
subjects with NSCLC who have progressed after responding to treatment with erlotinib.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
Not Recruiting
More
Objectives
- Primary: To evaluate the safety and tolerability of FG-3019 in combination with
gemcitabine and erlotinib
- Secondary: To evaluate the efficacy and pharmacokinetics of FG-3019 in combination with
gemcitabine and erlotinib
Stanford is currently not accepting patients for this trial.
For more information, please contact Donna Williams, 6504986608.
Stanford Investigators
View full details
-
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
Not Recruiting
More
The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive
brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive
matched placebo with TACE therapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Rebecca Bristol, 6507213114.
Stanford Investigators
View full details
-
Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination
Not Recruiting
More
Phase I study of SPARC1023 alone and in combination with carboplatin
Stanford is currently not accepting patients for this trial.
For more information, please contact Flordeliza Mendoza, 650-724-2056.
Stanford Investigators
View full details
-
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
Not Recruiting
More
Study is designed to determine the maximum tolerated dose (MTD) of SNX-5422 when given in
combination with everolimus.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Dauriac, 650-736-0697.
Stanford Investigators
View full details
-
Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
Not Recruiting
More
This randomized phase III trial is studying giving oxaliplatin, leucovorin, and fluorouracil
together with bevacizumab to see how well it works compared to oxaliplatin, leucovorin, and
fluorouracil alone in treating patients who have undergone surgery for stage II or stage III
colon cancer. Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil,
work in different ways to stop tumor cells from dividing so they stop growing or die.
Monoclonal antibodies such as bevacizumab can locate tumor cells and either kill them or
deliver tumor-killing substances to them without harming normal cells. Bevacizumab may also
stop the growth of tumor cells by stopping blood flow to the tumor. Giving chemotherapy
together with bevacizumab may kill more tumor cells. It is not yet known whether treatment
with oxaliplatin, leucovorin, and fluorouracil is more effective with or without bevacizumab
in treating patients who have undergone surgery for colon cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Marilyn Florero, 650-724-1953.
Stanford Investigators
View full details
-
TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
Not Recruiting
More
The primary objective of the study is to confirm that at least 1 or more doses of telotristat
etiprate compared to placebo is effective in reducing the number of daily bowel movements
(BMs) from baseline averaged over the 12-week double-blind portion (Treatment Period) of the
trial in patients not adequately controlled by current SSA therapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Hemamalini Vairamuthu, 650-723-0186.
Stanford Investigators
View full details
-
A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
Not Recruiting
More
This study will investigate the safety, symptoms and biomarker response of subjects with
biopsy-proven well-differentiated, low-to-intermediate-grade, unresectable, or metastatic
pancreatic neuroendocrine tumors (PNETs) or or Gastrointestinal Neuroendocrine tumors
(GI-NETs) with elevated biochemical markers who have relapsed during or after receiving prior
standard of care therapies, including octreotide, chemotherapy or targeted therapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ben Priestley, 650-723-2990.
Stanford Investigators
View full details
-
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Not Recruiting
More
This two-stage study is designed to compare the safety and activity between RRx-001 against
regorafenib followed by irinotecan-based therapies in a parallel comparative study.
Patients who are suffering from advanced or metastatic (meaning the disease has spread)
colorectal cancer are invited to participate in this study. There will be two groups of
patients (Randomized, open label study), one of these will receive RRx-001 and the other one
will receive regorafenib. If patients qualify to participate in this study, they will be
randomly assigned to the 'interventional arm' where patients will receive the experimental
drug, RRx-001, or the 'control arm' where they will receive the current standard-of-care,
Regorafenib. Patients have a 66% chance (2 out of 3) of receiving RRx-001 and a 33 % chance
(1 out of 3) of receiving regorafenib.
On progression in the first part of the study, provided ECOG performance status is adequate,
and if clinically appropriate i.e. there are no absolute or relative contraindications in the
opinion of the Investigator, all subjects will enter the second part of the study and receive
irinotecan plus bevacizumab.
Whether patients are given RRx-001 or regorafenib, they will also receive best supportive
care, which includes treatments to help manage side effects and symptoms of cancer. This is
an open label study, which means patients will know to which of these treatments, RRx-001 or
regorafenib, they are assigned.
Stanford is currently not accepting patients for this trial.
For more information, please contact Rachel Kasson, 650-723-0168.
Stanford Investigators
View full details
-
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Not Recruiting
More
The primary objective of this study is to evaluate the long-term safety and tolerability of
orally administered telotristat etiprate.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Dauriac, 650-736-0697.
Stanford Investigators
View full details
-
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Not Recruiting
More
This randomized phase II trial studies how well giving temozolomide with or without
capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors. Drugs
used in chemotherapy, such as temozolomide and capecitabine, work in different ways to stop
the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. It is not yet known whether temozolomide is more effective with
or without capecitabine in treating patients with advanced pancreatic neuroendocrine tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Benjamin Priestley, 650-723-2990.
Stanford Investigators
View full details
-
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
Not Recruiting
More
This randomized phase III trial studies how well radiation therapy, paclitaxel, and
carboplatin with or without trastuzumab work in treating patients with esophageal cancer.
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy,
such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Monoclonal antibodies, such as trastuzumab, may interfere with the ability of
tumor cells to grow and spread. It is not yet known whether giving radiation therapy and
combination chemotherapy together with or without trastuzumab is more effective in treating
esophageal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Polly Young, 650-497-7499.
Stanford Investigators
View full details
-
Evaluation of Stereotactic Radiosurgery For Liver Malignancies
Not Recruiting
More
This study is intended to establish the practicality of treating cancer in the liver with
precisely administered single fractions of high-energy radiation using a radiosurgical
(cross-firing) technique. A second purpose is to establish a safe dose for such therapy.
Finally, the efficacy of radiosurgical ablation of liver tumors, in terms of radiographic
response, will be measured.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jeff Kim, 6504987703.
Lead Sponsor
Stanford Investigators
View full details
-
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
Not Recruiting
More
The purpose of the study is to determine the safety, tolerability and maximum tolerated dose
of Urelumab in combination with Cetuximab in patients with Advanced/Metastatic Colorectal
Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck.
Stanford is currently not accepting patients for this trial.
For more information, please contact Risa Jiron, 650-736-1598.
Stanford Investigators
View full details
-
Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors
Not Recruiting
More
Cetuximab, erlotinib, and panitumumab are all recently FDA approved epidermal growth factor
receptor (EGFR) inhibitors that treat a wide variety of tumor types, such as colon, lung, and
head and neck. Blockade of the EGFR results in inhibition of multiple downstream pathways,
leading to slowed tumor growth. In addition, these inhibitors may enhance anti-tumor immune
responses through uncharacterized mechanisms. While producing significant responses in many
settings, EGFR inhibitors also result in significant skin toxicity (rash) in a high
percentage of patients. Multiple studies have correlated the presence and severity of rash
with clinical response. Unfortunately, severe rash can often lead to dose delays, reductions,
or even discontinuation of EGFR inhibitors, thus limiting their efficacy. The mechanism of
both the rash and its correlation with tumor response is poorly understood. Skin biopsies
display a robust leukocyte infiltrate, but a systematic analysis of the type of infiltrating
leukocytes, activation state, or homing receptor expression has not been performed.
Chemokines and chemokine receptors control leukocyte trafficking to the skin and other tissue
sites, and defined receptor profiles for skin-, gut-, and lung-homing leukocytes are well
established. In this study, the investigators propose to evaluate the homing phenotype of
leukocytes from peripheral blood and skin biopsies of patients receiving EGFR inhibitors. The
investigators will use RNA microarrays to evaluate the expression of chemokines and other key
genes regulated in skin during treatment. The investigators will utilize in vitro methods to
investigate effects of EGFR inhibitors on imprinting of T cell tissue-specific homing
receptors. The investigators will examine correlations among the pathologic data, clinical
findings, and tumor response. If validated, peripheral blood evaluation could potentially be
used as a predictive indicator for patients receiving EGFR inhibitors. This study may also
identify novel targets for limiting skin toxicity while receiving EGFR inhibitors, thus
allowing maximal dosing and clinical response from these agents.
Stanford is currently not accepting patients for this trial.
For more information, please contact Russell Pachynski, 6509066530.
Lead Sponsor
Stanford Investigators
View full details
-
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
Not Recruiting
More
The standard treatment for locally advanced rectal cancer involves chemotherapy and
radiation, known as 5FUCMT, (the chemotherapy drugs 5-fluorouracil/capecitabine and radiation
therapy) prior to surgery. Although radiation therapy to the pelvis has been a standard and
important part of treatment for rectal cancer and has been shown to decrease the risk of the
cancer coming back in the same area in the pelvis, some patients experience undesirable side
effects from the radiation and there have been important advances in chemotherapy, surgery,
and radiation which may be of benefit. The purpose of this study is to compare the effects,
both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy
using a combination regimen known as FOLFOX, (the drugs 5-fluorouracil (5-FU), oxaliplatin
and leucovorin) and selective use of the standard treatment, depending on response to the
FOLFOX. The drugs in the FOLFOX regimen are all FDA (Food and Drug Administration) approved
and have been used routinely to treat patients with advanced colorectal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ben Priestley, 650-723-2990.
Stanford Investigators
View full details
-
Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer
Not Recruiting
More
Treatment of rectal cancer often consists of surgical resection of the tumor. Chemotherapy
and/or radiotherapy are frequently given before or after surgery. In this study, we wish to
learn if there are differences in the treatment effectiveness or in the quality of life of
patients based on their type of treatment (e.g. Radiotherapy and chemotherapy before or after
surgery). Information from this questionnaire collected from you and other patients may help
improve the quality of life of rectal cancer patients in the future. Medical information on
your tumor, treatment received, and side effects will be compiled and maintained in a
database to learn more about outcomes of treatment for rectal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Moe Jalali, 6507244023.
Lead Sponsor
Stanford Investigators
View full details
-
Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
Not Recruiting
More
The purpose of this study is first, to determine whether baseline perfusion characteristics
of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to
treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to
determine whether baseline perfusion characteristics in those patients with resectable
pancreatic cancer correlate with immunohistologic markers of angiogenesis such as microvessel
density and vascular endothelial growth factor (VEGF) expression.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lindee Burton, 6507254712.
Lead Sponsor
Stanford Investigators
View full details
-
Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors
Not Recruiting
More
Given the lack of other viable treatment options for metastatic neuroendocrine tumors,
contrasted with our positive anecdotal experience, and the relative tolerability of the
treatment regimen for colorectal cancer patients, we propose a single-institution phase II
trial investigating the efficacy of capecitabine, oxaliplatin and bevacizumab for patients
with metastatic neuroendocrine tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Heidi Kaiser, 6507240079.
Stanford Investigators
View full details
-
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Not Recruiting
More
To determine objective response rates (RR) by RECIST guideline version 1.1 for all patients
treated with this strategy consisting of initial therapy with pertuzumab as a single agent
and then addition of erlotinib for those who have stable disease or progressive disease at
three months (Simon design).
Stanford is currently not accepting patients for this trial.
For more information, please contact Heidi Kaiser, 6507240079.
Stanford Investigators
View full details
-
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
Not Recruiting
More
The purpose of this study is to learn whether it is safe and effective to administer HKI-272
(neratinib) in combination with paclitaxel in patients with breast cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mary Chen, 6507238686.
Stanford Investigators
View full details
-
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as capecitabine and gemcitabine, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells.
Specialized radiation therapy that delivers a high dose of radiation directly to the tumor
may kill more tumor cells and cause less damage to normal tissue. Giving more than one drug
(combination chemotherapy) together with radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving capecitabine together with
gemcitabine followed by capecitabine and radiation therapy works in treating patients with
cholangiocarcinoma of the gallbladder or bile duct.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 6507360798.
Stanford Investigators
View full details
-
Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
Not Recruiting
More
The purpose of this study is to determine progression-free survival at 12 months for
stereotactic body radiotherapy (SBRT) and chemotherapy for unresectable hilar
cholangiocarcinoma (CCA).
Stanford is currently not accepting patients for this trial.
For more information, please contact Laurie Ann Columbo, 6507360792.
Lead Sponsor
Stanford Investigators
View full details
-
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
Not Recruiting
More
This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme
versus placebo in patients with hepatocellular carcinoma who have failed prior systemic
treatment (chemotherapy). Hepatocellular carcinomas have been found to require arginine, an
amino acid. Thus the hypothesis is that by restricting arginine with ADI-PEG 20, the
hepatocellular carcinoma cells will starve and die.
Stanford is currently not accepting patients for this trial.
For more information, please contact Flordeliza Mendoza, 650-724-2056.
Stanford Investigators
View full details
-
Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers
Not Recruiting
More
We have an active research program in gastrointestinal cancers including clinical trials,
epidemiologic, and translational studies. We would like to establish a biospecimen bank
linked to useful clinical information in order to learn more about diagnostic, predictive and
prognostic markers for gastrointestinal cancers.
PRIMARY OBJECTIVES:
1. To collect and store tumor and normal tissue (previously collected paraffin embedded or
frozen specimen) and blood in patients with gastrointestinal (GI) cancers.
SECONDARY OBJECTIVES:
1. Collect detailed clinical information via a patient questionnaire that includes
demographic, socioeconomic, lifestyle, family, past medical, medication and cancer
histories
2. Collect details about the tumor specimen extracted from patient charts.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Pitsiouni, 6504986000.
Lead Sponsor
Stanford Investigators
View full details
-
Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
Not Recruiting
More
Primary Objective:
To compare the efficacy of TACE vs. CyberKnife SBRT in the treatment of locally recurrent HCC
after initial TACE.
Secondary Objectives:
1. To determine the progression-free survival of TACE vs. CyberKnife SBRT
2. To determine the overall survival of TACE vs. CyberKnife SBRT for locally recurrent HCC
3. To determine the toxicities associated with TACE or CyberKnife SBRT for the treatment of
recurrent HCC.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laurie Ann Columbo, 6507360792.
Stanford Investigators
View full details
-
Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma
Not Recruiting
More
To determine the efficacy and toxicity of TACE combined with SBRT
Stanford is currently not accepting patients for this trial.
For more information, please contact Laurie Ann Columbo, 650-736-0792.
Lead Sponsor
Stanford Investigators
View full details
-
Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer
Not Recruiting
More
Single-institution phase 2 trial investigating the efficacy of capecitabine, oxaliplatin and
bevacizumab for patients with metastatic neuroendocrine tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mary Chen, 6507238686.
Stanford Investigators
View full details
-
Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast
Not Recruiting
More
In order to improve the survival of metastatic breast patients, it is important to
investigate the use of novel therapeutic agents combined with known active agents in the
treatment of breast cancer. This is a phase I study evaluating the maximum tolerated doses
and toxicities of RAD001 in combination with capecitabine for the treatment of metastatic
breast cancer. RAD001 (INN: everolimus) is a novel macrolide, which is being developed as an
antiproliferative drug with applications as an immunosuppressant and anticancer agent. Phase
I trials in patients with solid tumors have shown that treatment with RAD001 is
well-tolerated with a minimal side effect profile. Capecitabine (Xeloda, Roche) is an oral
fluoropyrimidine that was approved in 1998 for the treatment of patients with metastatic
breast cancer. The all-oral regimen of RAD001 with capecitabine is an attractive approach as
the treatment of metastatic breast cancer has not yet proven to be curative. We also want to
find out what possible benefit this combination of drugs might have on treating your cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mary Chen, 6507238686.
Lead Sponsor
Stanford Investigators
View full details
-
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
Not Recruiting
More
This trial combines dose dense chemotherapy with doxorubicin and cyclophosphamide (AC)
followed by standard, every 3 week docetaxel and GW572016 (lapatinib) for neoadjuvant
treatment of Her2neu positive stage II/III breast cancer. The purpose of the study was to
determine whether lapatinib combined with chemotherapy was safe and resulted in an increase
in pathologic complete response rates.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mary Chen, 6507238686.
Stanford Investigators
View full details
-
Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer
Not Recruiting
More
To determine the maximum tolerated dose of Vandetanib with a current standard first-line
chemotherapy regimen, capecitabine and oxaliplatin without and then with bevacizumab for the
first line treatment of metastatic colorectal cancer (CRC) and to define the dose limiting
toxicities associated with the combination.
Stanford is currently not accepting patients for this trial.
For more information, please contact Heidi Kaiser, 6507240079.
Stanford Investigators
View full details
-
Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Not Recruiting
More
The primary objective of this study is to compare the additive efficacy of SIM versus placebo
in combination with leucovorin (folinic acid), irinotecan, and fluorouracil (FOLFIRI) as
measured by improvement in progression-free survival (PFS) in participants with metastatic
KRAS mutant colorectal adenocarcinoma who have progressed following a first-line oxaliplatin-
and fluoropyrimidine-containing regimen.
Stanford is currently not accepting patients for this trial.
For more information, please contact Heidi Kaiser, 6507240079.
Stanford Investigators
View full details
-
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
Not Recruiting
More
This is a Phase 2, multicenter, multiple-arm, open-label study to evaluate the efficacy,
safety, and tolerability of EZN-2208. EZN-2208 will be administered as a single agent in
patients with K-RAS mutations in the tumors. Patients with wild type K-RAS in tumors will be
randomized to EZN-2208 + cetuximab or to standard of care (Camptosar® + cetuximab), patients
must have failed regimens containing irinotecan (Camptosar®, CPT-11), oxaliplatin
(Eloxatin®), and fluoropyrimidine.
After discontinuation of study treatment, patients will receive care as considered
appropriate by the investigator. Patients will continue to be followed for disease
progression, subsequent anticancer therapy, and survival.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Pitsiouni, 6507213114.
Stanford Investigators
View full details
-
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
Not Recruiting
More
A safety & efficacy clinical study of the investigational medicinal product BYM338 for the
treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Not Recruiting
More
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known
whether treatment with interferon alfa is more effective than observation alone for stage II
or stage III melanoma that has been completely removed surgically.
PURPOSE: This randomized phase III trial is studying high dose interferon alfa to see how
well it works compared to observation only in treating patients with stage II or stage III
melanoma that has been completely removed by surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sunil Arani Reddy, 6507361234.
Stanford Investigators
View full details
-
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Not Recruiting
More
The purpose of this study was to determine whether monthly deep subcutaneous (s.c.)
injections of lanreotide Autogel (Somatuline Depot) were effective and safe in controlling
diarrhoea and flushing by reducing the usage of s.c. short-acting octreotide as a rescue
medication to control symptoms in subjects with carcinoid syndrome.
Stanford is currently not accepting patients for this trial.
For more information, please contact Heidi Kaiser, 6507240079.
Stanford Investigators
View full details
-
Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
Not Recruiting
More
The purpose of this study is to determine the best confirmed response rate of daily
administration of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR and
VEGFR2) XL647 in subjects with NSCLC who have progressed after responding to treatment with
either erlotinib or gefitinib.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer
Not Recruiting
More
The purpose of this study is to determine if adding ASA404 to docetaxel chemotherapy makes
the cancer treatment more effective in patients with locally advanced or metastatic non-small
cell lung cancer
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Not Recruiting
More
The purpose of this study is to assess overall survival after treatment with a regimen of
adjuvant therapy (Gemcitabine alone or with 5-FU chemoradiation) with or without
HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in subjects who have undergone surgical
resection.
Stanford is currently not accepting patients for this trial.
For more information, please contact Donna Williams, 6504986608.
Stanford Investigators
View full details
-
Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer
Not Recruiting
More
The purpose of the trial is to test the efficacy of combining conventional chemoradiotherapy
with radiosurgery for locally advanced pancreas cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Stanford Cancer Clinical Trials Office, 6504987061.
Lead Sponsor
Stanford Investigators
View full details
-
Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
Not Recruiting
More
The purpose of the study is to determine the optimal safe and tolerable dose of gemcitabine
in combination with once daily or twice daily dose of PTK/ZK in patients with unresectable
pancreatic cancer. The Phase II part of this study planned to determine the antitumor
activity of this regimen and its effectiveness of preventing tumor growth and spread.
Stanford is currently not accepting patients for this trial.
For more information, please contact Heidi Kaiser, 6507240079.
Stanford Investigators
View full details
-
Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer
Not Recruiting
More
This study will assess the efficacy of treating locally advanced pancreatic cancer using
Stereotactic Body Radiotherapy (using Trilogy) and Gemcitabine
Stanford is currently not accepting patients for this trial.
For more information, please contact Jeff Kim, 6504987703.
Stanford Investigators
View full details
-
A Study of Nilotinib Versus Imatinib in GIST Patients
Not Recruiting
More
This study will evaluate efficacy and safety of nilotinib versus imatinib in adult patients
with unresectable or metastatic gastrointestinal stromal tumors (GIST).
Stanford is currently not accepting patients for this trial.
For more information, please contact Heidi Kaiser, 6507240079.
Stanford Investigators
View full details
-
Study of Cobimetinib in Participants With Solid Tumors
Not Recruiting
More
This non-randomized, open-label, study will determine the highest safe dose of cobimetinib,
how often it should be taken, how well participants with cancer tolerate cobimetinib and will
assess the pharmacokinetic effect of midazolam and dextromethorphan on the study drug.
Stanford is currently not accepting patients for this trial.
For more information, please contact Dana Supan, 6507361694.
Stanford Investigators
View full details
-
Study of XL647 Administered Orally Daily to Patients With Solid Tumors
Not Recruiting
More
The purpose of this study is to assess the safety and tolerability of the multiple receptor
tyrosine kinase (RTK) inhibitor (including EGFR, VEGFR2, ErbB2, and EphB4) XL647 when given
orally daily to adults with advanced solid tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joanne Fehling, 6507361694.
Stanford Investigators
View full details
-
A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
Not Recruiting
More
A phase 2 study combining pertuzumab with erlotinib for patients with gemcitabine refractory
pancreatic adenocarcinoma
Stanford is currently not accepting patients for this trial.
For more information, please contact Donna Collins Williams, 6504986608.
Stanford Investigators
View full details
-
A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Not Recruiting
More
This study will compare the efficacy of simtuzumab (GS-6624) versus placebo in combination
with gemcitabine in adults with pancreatic cancer. The treatment phase of this study will be
comprised of 2 sequential parts: an open label treatment phase and a double-blinded treatment
phase.
Stanford is currently not accepting patients for this trial.
For more information, please contact Donna Collins Williams, 6504986608.
Stanford Investigators
View full details
-
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
Not Recruiting
More
The purpose of the study was to determine whether the combination of aflibercept, pemetrexed
and cisplatin is safe and effective in treating non-small cell lung cancer (NSCLC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
